

Efficient Asymmetric Synthesis of Phosphatidyl-D-*myo*-inositol 3,4,5-trisphosphate

Takayuki SAWADA, Ryuichi SHIRAI, and Shigeo IWASAKI*

Institute of Molecular and Cellular Biosciences (IMCB), The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113, Japan. Received January 20, 1997; accepted April 9, 1997

Phosphatidyl-D-*myo*-inositol 3,4,5-trisphosphate, a candidate of the second messenger in cellular signal transduction, was efficiently synthesized in a homochiral form.

Key words phosphatidyl-D-*myo*-inositol 3,4,5-trisphosphate; phosphatidyl-D-*myo*-inositol 3-kinase; cellular signal transduction; second messenger

Polyphosphoinositides play an extremely important role in cellular signal transduction. Recently, it has been revealed that phosphatidyl-D-*myo*-inositol 3-kinase (PI 3-kinase) catalyzes the phosphorylation of phosphatidyl-D-*myo*-inositol 4,5-bisphosphate (PI 4,5-P₂) to phosphatidyl-D-*myo*-inositol 3,4,5-trisphosphate (PI 3,4,5-P₃; **1**).¹⁾ Stephens *et al.* reported that PIP₃ 5-phosphatase dephosphorylates **1** to phosphatidyl-D-*myo*-inositol 3,4-bisphosphate (PI 3,4-P₂).²⁾ Interestingly, **1** is resistant to known phospholipase Cs, and no other enzyme that metabolizes **1** has so far been found. Although the role and function of **1** remain unknown, it is a promising candidate for a second messenger in cellular signal transduction.

Many biological studies of PI 3-kinase have been reported, but there are only a few reports on the function of its product **1**.^{3,4)} Since the availability of **1** is severely limited, an efficient chemical synthesis is required. Recently, we reported the synthesis of 1-*O*-alkyl and 1-*O*-acyl-D-*myo*-inositol 3,4,5-trisphosphates,⁵⁾ which might serve as alternatives to **1** in studies of **1** and PI 3-kinase. Here, we present an efficient asymmetric synthesis of **1b**⁶⁻⁹⁾ with saturated lipid side chains from the chiral *myo*-inositol intermediate **3** developed by Prestwich and co-workers.¹⁰⁾

Results and Discussion

The synthetic scheme of **1b** is depicted in Chart 2. The appropriately protected homochiral key intermediate **3** was synthesized according to Prestwich's method¹⁰⁾ from methyl α -D-glucopyranoside **2** through 9 steps in 26% overall yield. The amidite **7** with two stearoyl groups was obtained from 1,2-stearoyl-*sn*-glycerol and benzyl *N,N,N',N'*-tetraisopropylphosphoramidite, which were prepared from (*S*)-(+)-2,2-dimethyldioxolane-4-methanol and phosphorus trichloride, respectively.^{9,11)} The coupling of the inositol derivative **3** with the amidite **7** followed by *m*-chloroperbenzoic acids (*m*-CPBA) oxidation in one pot gave an epimeric mixture of **4**.¹²⁾ Removal of the *p*-methoxybenzyl (PMB) groups with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)¹³⁾ in wet CH₂Cl₂ gave the triol **5**. Phosphitylation of the resulting triol with dibenzyl *N,N*-diethylphosphoramidite, followed by oxidation with *m*-CPBA in one pot gave fully protected PI 3,4,5-P₃ (**6**). Deprotection of all benzyl (Bn) and benzyloxymethyl (BOM) groups of **6** was carried out cleanly by hydrogenolysis over Pd black in *tert*-BuOH in the presence of NaHCO₃.⁹⁾ During the hydrogenolysis, partially or fully deprotected sodium salts precipitated. To obtain complete

deprotection to **1b**, a small amount of water was added after 2 h to dissolve insoluble salts. The overall yield of **1b** from **2** was 21% through 13 steps.


The synthesis described here should provide easy access to a variety of derivatives of **1b**. Clarification of the function of **1** in cellular signal transduction is in progress and the results will be reported elsewhere.

Experimental

¹H- and ³¹P-NMR spectra were recorded on a JEOL JNM-A500 spectrometer with tetramethylsilane (¹H) and H₃PO₄ (³¹P) as internal standards, respectively. The chemical shift values are expressed as δ (ppm) values. Multiplicities are indicated by s (singlet), d (doublet), t (triplet), m (multiplet), br (broad). FAB-MS or HR FAB-MS were measured on a JEOL JMS-HX110 spectrometer.

1,2-Di-*O*-stearoyl-*sn*-glycerol Benzyl *N,N*-Diisopropylphosphoramidite (7**)** According to the procedure described in ref. 9, coupling of 1,2-di-*O*-stearoyl-*sn*-glycerol (300 mg, 0.48 mmol) with benzyl *N,N,N',N'*-tetraisopropylphosphoramidite (320 mg, 0.96 mmol) in the presence of 1*H*-tetrazole (68 mg, 0.97 mmol) gave **7** (409 mg, 0.48 mmol, 99%) as a colorless oil. ¹H-NMR (CDCl₃) δ : 0.88 (6H, t, 7.0 Hz), 1.17 (12H, m), 1.24—1.30 (56H, br m), 1.60 (4H, m), 2.28 (2H, t, 6.0 Hz), 2.29 (2H, t, 6.0 Hz), 3.58—3.82 (4H, m), 4.17 (1H, m), 4.34 (1H, m), 4.63—4.76 (2H, m), 5.19 (1H, m), 7.23—7.39 (5H, m).


2,6-Di-*O*-benzyloxymethyl-3,4,5-tri-*O*-*p*-methoxybenzyl-D-*myo*-inositol 1-*O*-(1,2-Di-*O*-stearoyl-*sn*-glycerol Benzylphosphate) (4**)** Anhydrous CH₂Cl₂ (10 ml) was added to a mixture of anhydrous **7** (409 mg, 0.48 mmol, dried by azeotropic removal of water with benzene), 2,6-di-*O*-benzyloxymethyl-3,4,5-tri-*O*-*p*-methoxybenzyl-D-*myo*-inositol (**3**) (185 mg, 0.24 mmol) prepared by Prestwich's procedure¹⁰⁾ and 1*H*-tetrazole (120 mg, 1.70 mmol). After 30 min, a small amount of water was added. The mixture was further stirred for 30 min, then *m*-CPBA (330 mg, 1.34 mmol) was added at -40°C, and the reaction mixture was allowed to warm to room temperature. It was extracted with AcOEt, and the organic solution was washed with aqueous 10% Na₂SO₃ and aqueous saturated NaHCO₃, then dried over anhydrous MgSO₄. The solvent was removed *in vacuo* and the residue was purified by silica gel column chromatography with 5% AcOEt in hexane to give **4**. ¹H-NMR (CDCl₃) δ : 0.88 (6H, t, 7 Hz), 1.21—1.31 (56H, br), 1.50—1.59 (4H, m), 2.17—2.25 (4H, m), 3.38—3.43 (2H, m), 3.77 (9H, s), 3.91—4.25 (8H, m), 4.43—5.17 (17H, m), 6.78—6.82 (6H, m), 7.17—7.32 (21H, m).



phosphatidylinositol 3,4,5-trisphosphate

Chart 1

* To whom correspondence should be addressed.



Reagents and conditions: **a.** 1H-tetrazole, CH₂Cl₂, r.t., 30 min, then *m*-CPBA, -40°C to r.t.
b. DDQ, wet CH₂Cl₂, r.t., 1h. **c.** (BnO)₂PNET₂, 1H-tetrazole, CH₂Cl₂, r.t., 30 min; then *m*-CPBA, -40°C to r.t. **d.** H₂ (50 psi), Pd black, NaHCO₃, 85% *t*-BuOH/H₂O

Chart 2

IR (CHCl₃) cm⁻¹: 2900, 2870, 2830, 1740, 1610, 1590, 1510, 1460, 1360, 1300, 1240—1200, 1170, 1110, 1030, 920. FAB-MS (*m*-nitrobenzylalcohol (*m*NBA)) *m/z*: 1579, 1580 (M + Na). HR FAB-MS *m/z*: Calcd for C₉₂H₁₃₃NaO₁₈P, 1579.9127, Found 1579.9169.

2,6-Di-*O*-benzyloxymethyl-D-*myo*-inositol 1-*O*-(1,2-Di-*O*-stearoyl-*sn*-glycerol Benzylphosphate) (5) A solution of **4** in wet CH₂Cl₂ 5 ml at room temperature was treated with 95% DDQ (440 mg, 1.84 mmol). After having been stirred for 1 h, the reaction mixture was poured into aqueous saturated NaHCO₃ and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous MgSO₄ and concentrated *in vacuo*. The residue was purified by silica gel column chromatography with 60% AcOEt in hexane to give **5** (254 mg, 0.21 mmol, 90% from **3**). ¹H-NMR (CDCl₃) δ: 0.88 (6H, t, 7.0 Hz), 1.23—1.27 (56H, br m), 1.53—1.60 (4H, br), 1.86 (1H, br), 2.22—2.28 (4H, m), 3.01 (1H, br), 3.34—3.44 (2H, m), 3.50 (1H, br), 3.70 (1H, t, 9.0 Hz), 3.78—3.85 (1H, m), 4.04—4.31 (7H, m), 4.53—5.09 (9H, m), 5.15 (1H, m), 7.27—7.35 (15H, m). IR (CHCl₃) cm⁻¹: 2920, 2850, 2400, 1740, 1460, 1380, 1160, 1110, 1020, 920. FAB-MS (*m*NBA) *m/z*: 1219 (M + Na). HR FAB-MS *m/z*: Calcd for C₆₈H₁₀₉NaO₁₅P, 1219.7402, Found 1219.7417.

2,6-Di-*O*-benzyloxymethyl-3,4,5-tris-*O*-(dibenzylphosphoryl)-D-*myo*-inositol 1-*O*-(1,2-Di-*O*-stearoyl-*sn*-glycerol Benzyl Phosphate) (6) Dibenzyl *N,N*-diethylphosphoramidite (0.10 ml, 0.39 mmol) was added to a mixture of **5** (54 mg, 0.042 mmol) and 1H-tetrazole (50 mg, 0.71 mmol) in 3 ml of dry CH₂Cl₂ at room temperature. The mixture was stirred for 30 min, then a small amount of water was added. After additional stirring for 10 min, the mixture was treated with *m*-CPBA (100 mg, 0.41 mmol) at -40°C, and the whole was allowed to warm to room temperature. It was extracted with AcOEt, washed with aqueous 10% Na₂SO₃, aqueous saturated NaHCO₃ and brine, and dried over anhydrous MgSO₄. The solvent was removed *in vacuo* and the residue was purified by silica gel column chromatography with 30% AcOEt in CH₂Cl₂ to give **6** (69 mg, 0.035 mmol, 84%). ¹H-NMR δ (CDCl₃): 0.80—0.90 (6H, br), 1.10—1.40 (56H, br), 1.50—1.70 (4H, br), 2.20 (4H, br), 2.90—3.10 (2H, br), 3.90—5.10 (31H, br m), 7.10—7.40 (45H, br m). IR (CHCl₃) cm⁻¹: 2940, 2860, 1740, 1600, 1500, 1460, 1380, 1270, 1080. FAB-MS

(*m*NBA) *m/z*: 1999 and 2000 (M + Na), 1977 (M + H). HR FAB-MS *m/z*: Calcd for C₁₁₀H₁₄₈NaO₂₄P₄, 1999.9209, Found 1999.9206.

3,4,5-Tris-*O*-phosphoryl-D-*myo*-inositol 1-*O*-(1,2-Di-*O*-stearoyl-*sn*-glycerol Phosphate) Sodium Salt (1b (Na)) Pd black (28 mg) and NaHCO₃ (6.4 mg, 0.078 mmol) were added to a solution of **6** (22 mg, 0.011 mmol) in 8.3 ml of 85% *tert*-BuOH in water, and the mixture was shaken under H₂ (50 psi) for 3 h. Precipitated insoluble sodium salts were dissolved by the addition of water and the mixture was shaken again under H₂ (50 psi) for a further 3 h. The catalyst was removed by filtration and washed with EtOH and water. The filtrate was concentrated *in vacuo* and lyophilized to give **1b (Na)** as the heptasodium salt. (13.6 mg). ¹H-NMR (D₂O) δ: 0.70 (6H, br), 1.00—1.50 (60H, br), 2.10—2.40 (4H, br), 3.80—4.50 (9H, br m), 5.20 (1H, br). ³¹P-NMR (D₂O) δ: -0.127, 1.984, 3.563, 4.419. Negative FAB-MS *m/z*: 1105 (M - H), 1127 (M + Na - 2H), 1149 (M + 2Na - 3H), 1171 (M + 3Na - 4H).

Acknowledgments We are grateful to Dr. Naoko Morisaki for FAB-MS and HRFAB-MS measurements, and to Dr. Kazuo Furihata for ³¹P NMR measurements.

References

- 1) Kapeller R., Cantley L. C., *BioEssays*, **16**, 565—576 (1994).
- 2) Stephens L. R., Hughes K. T., Irvine R. F., *Nature* (London), **351**, 33—39 (1991).
- 3) a) Singh S. S., Chauhan A., Brockerhoff H., Chauhan V. P. S., *Biochem. Biophys. Res. Commun.*, **195**, 104—112 (1993); b) Nakanishi H., Brewer K. A., Exton J. H., *J. Biol. Chem.*, **268**, 13—16 (1993); c) Toker A., Meyer M., Reddy K. K., Falck J. R., Aneja R., Aneja S., Parra A., Burns D. J., Ballas L. M., Cantley L. C., *ibid.*, **269**, 32358—32367 (1994).
- 4) Burgering B. M. Th., Coffey P. J., *Nature* (London), **376**, 599—602 (1995).
- 5) Sawada T., Shirai R., Matsuo Y., Kabuyama Y., Kimura K., Fukui Y., Hashimoto Y., Iwasaki S., *BioMed. Chem. Lett.*, **5**, 2263—2266 (1995).
- 6) Gou D.-M., Chen C.-S., *J. Chem. Soc., Chem. Commun.*, **1994**,

- 2125—2126.
- 7) Watanabe Y., Tomioka M., Ozaki S., *Tetrahedron*, **51**, 8969—8976 (1995).
- 8) Falck J. R., Abdali A., "Inositol Phosphates and Derivatives, Synthesis, Biochemistry and Therapeutic Potential," ed. by Reitz A. B., American Chemical Society; Washington DC, **1991**, pp. 145—154.
- 9) Reddy K. K., Saady M., Falck J. R., Whited G., *J. Org. Chem.*, **60**, 3385—3390 (1995).
- 10) Estevez V. A., Prestwich G. D., *J. Am. Chem. Soc.*, **113**, 9885—9887 (1991); Chen J., Profit A. A., Prestwich G. D., *J. Org. Chem.*, **61**, 6305—6312 (1996). See also, Bender S. L., Budhu R. J., *J. Am. Chem. Soc.*, **113**, 9883—9885 (1991).
- 11) Bannwarth W., Trzeciak A., *Helv. Chim. Acta*, **70**, 175—186 (1987).
- 12) Bruzik K. S., Salamonczyk G., Stec W. J., *J. Org. Chem.*, **51**, 2368—2370 (1986).
- 13) Oikawa Y., Yoshioka T., Yonemitsu O., *Tetrahedron Lett.*, **23**, 885—888 (1982).